Press release

Correction: Oncopeptides presents new data at the European Haematology Association meeting

May 12, 2023

Updated information

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that new scientific data on melflufen has been accepted at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023. The data includes one clinical abstract on final efficacy and safety data from the phase 1/2 ANCHOR study, and one preclinical abstract on melflufen showing efficacy in association with decreased and mutated TP53 activity and enrichment of genes involved in DNA damage repair.

The abstracts are available on the following link (search with the abstract code): EHA Open Access Library.

ANCHOR is a phase 1/2 open label multicenter study evaluating the safety and efficacy of melflufen plus dexamethasone in combination with either daratumumab or bortezomib in patients with relapsed refractory multiple myeloma (RRMM). The study started in April 2018 and was prematurely closed in February 2022 with 56 patients enrolled. The final analysis continues to support the previously reported efficacy and safety data that subsequently led to the initiation of the confirmatory phase 3 LIGHTHOUSE trial. Data from the LIGHTHOUSE study was recently presented at the European Myeloma Network meeting.

“The triplet combination of melflufen plus dexamethasone and daratumumab or bortezomib, showed encouraging clinical activity in patients with RRMM who previously have received 1-4 prior lines of therapy,” says Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. “The triplet combinations with melflufen showed a predictable and manageable safety profile, which are important factors for patients in later lines of therapies.”

Scientific abstract  First author  Abstract type Abstract code 
ANCHOR (op-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final efficacy and safety results. Prof. Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. Poster presentation P876
Sensitivity of multiple myeloma to melflufen associates with decreased P53 activity and enrichment of DNA damage repair pathway genes Mr. Juho Miettinen, Institute for Molecular Medicine Finland (FiMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland Publication only PB2071